I'm one of the "bailers"! My reasons are:
1. EBITDA will be lower than pcp
Revenue
They didn't give a revenue number for the 1Q and said revenue for the 2Q was stated to be $11.3m; the receipts from customers in the June 4C was $15m ; that's $26.3m. I struggle to see a revenue for the half more than 1H 2018 which was $33m.
Costs:
COS% for FY 2018 was 65%; use that
S&M, R&D, Admin total cost in the 2H 2018 was $25m; can't see it any lower in 1H 2019
2. They are signalling that the Ivory Close project will not close before the end of 3Q so no profitability in the 4 Q as previously guided.
3. I can't think my way through the ownership issues around San Quintin in Mexico.
So I reckon the FLC SP will be weak for another 6 months; maybe back to the 30's.
50 cents was my breakeven; so I bailed for 75% of my holding. FLC is likely to be a good investment but, for me, not now so much!
- Forums
- ASX - By Stock
- FLC
- Ann: Fluence June 2019 Quarterly Report Business Update
FLC
fluence corporation limited
Add to My Watchlist
4.88%
!
3.9¢

Ann: Fluence June 2019 Quarterly Report Business Update, page-104
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
3.9¢ |
Change
-0.002(4.88%) |
Mkt cap ! $42.32M |
Open | High | Low | Value | Volume |
4.1¢ | 4.1¢ | 3.8¢ | $17.54K | 451.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 6812 | 3.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.2¢ | 161616 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 6812 | 0.039 |
1 | 13250 | 0.038 |
2 | 370000 | 0.037 |
1 | 350000 | 0.036 |
2 | 220000 | 0.035 |
Price($) | Vol. | No. |
---|---|---|
0.042 | 161616 | 4 |
0.043 | 120000 | 1 |
0.045 | 25000 | 1 |
0.047 | 2224 | 1 |
0.050 | 67600 | 1 |
Last trade - 15.51pm 27/06/2025 (20 minute delay) ? |
Featured News
FLC (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online